Soutenance HDR de Gaëlle Fiard le 12/10/20

Gaëlle Fiard from TIMC GMCAO team will present her HDR defense (Habilitation to Lead Research), on October 12, 2020 at 2:00 pm : 

« Early Diagnosis and Focused Treatment of Prostate Cancer . »


bullet Place: Salle des thèses (109) du bâtiment Boucherle. Attention!, capacity limited to 20 people

bullet Jury:  

  • Sandrine Voros, Chargée de Recherche INSERM, laboratoire TIMC, Communauté Université Grenoble Alpes, Reporter
  • Pierre Mozer, Professeur des Universités-Praticien Hospitalier à l’AP-HP, La Pitié Salpêtrière, Paris, Reporter
  • Olivier Rouvière, Professeur-Praticien Hospitalier, Hospices Civils de Lyon, Reporter
  • Jocelyne Troccaz, Directrice de Recherche CNRS, laboratoire TIMC, Université Grenoble Alpes, Examiner
  • Jean-Luc Descotes, Professeur des Universités-Praticien Hospitalier, laboratoire TIMC, CHU Grenoble Alpes, Examiner
  • Laurent Guy, Professeur-Praticien Hospitalier, CHU de Clermont-Ferrand, Examiner


bullet Abstract:  

Prostate cancer is the most common malignancy among men in France and the third cause of cancer-related death. Screening is not recommended, and around 8000 patients die each year of cancer diagnosed at a metastatic stage or after metastatic evolution of a localized or locally-advanced disease. The controversy surrounding screening finds its source in multiple factors, mostly due to the lack in precision of the biological test used (PSA testing) and the confirmatory biopsy procedure (systematic biopsies). Finally, radical treatments (radical prostatectomy, radiotherapy) are known for causing significant urinary and sexual side-effects, reducing the benefit of early cancer detection. There are numerous opportunities of improvement that have been considered, are under scrutiny or will be studied by this research work. We will discuss the improvement in early detection by prostate magnetic resonance imaging and targeted biopsies, the enhancement of initial training for prostate biopsy by simulation, and a better understanding of the mechanisms behind tumor visibility on imaging by looking at the effects of aging and senescent cells in the prostate. Finally, we will focus on focal therapy and the evaluation of sexual outcomes after focal treatment. We will conclude by pondering future screening opportunities and the place of focal therapy in the future for the management of prostate cancer.